Tempus Reports Fourth Quarter and Full Year 2025 Results

About this update from Ai, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/0306459989c3010a54c020b5b6731f91"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gpfW0s_LcphTtUKl005DZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0306459989c3010a54c020b5b6731f91","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/UQdAQc_EeXiJ2iW71y83jw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/0306459989c3010a54c020b5b6731f91","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, February 24, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025.","length":254,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry)","length":109,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":109,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Diagnostics revenue of $266.9 million in the fourth quarter, representing 121.6% growth year-over-year, driven by Oncology volume growth of 29% and Hereditary volume growth of 23%","length":179,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":179,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"MRD volume was ~4,700 tests in the fourth quarter, up 56% quarter-over-quarter","length":78,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":78,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Data and Applications revenue of $100.4 million in the fourth quarter, representing 25.1% year-over-year growth, with Insights (data licensing) growing 69.5%, excluding the impact of the AstraZeneca warrant in Q4 of 2024","length":220,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":220,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Ended the year with over $1....

More updates from Ai, Inc.